Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Zydus receives final approval from the USFDA forErythromycin Tablets USP, 250 mg and 500 mg".
Press Release Mar 09 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Erythromycin Tablets USP in two dosages. These tablets are used to treat various infections, including respiratory and skin infections. The manufacturing will take place at Zydus's facility in Moraiya, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 07 2023
- Press Release Mar 03 2023
- Press Release Mar 02 2023
- Press Release Feb 28 2023
- Press Release Feb 24 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Mar 15 2023
- Press Release Mar 21 2023
- Press Release Mar 24 2023
- Press Release Mar 25 2023
- Press Release Mar 28 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences